Objective: To systematically review the evidence concerning the diagnostic yield of genetic and metabolic evaluation of children with global developmental delay or intellectual disability (GDD/ID).
Children aged less than 6 years are considered to have global developmental delay (GDD) if they perform more than 2 SDs below age-matched peers in 2 or more aspects of development. 1, 2 GDD affects an estimated 1%-3% of children, many of whom will demonstrate intellectual disability (ID). 1, 2 In this evidence report, a developmental quotient (DQ) or IQ of 50 -70 is considered mild impairment, and a DQ or IQ of less than 50 is considered moderate to severe impairment.
The previous American Academy of Neurology and Child Neurology Society guideline regarding evaluation of GDD concluded that several diagnostic tests had a greater than 1% yield, including G-banded karyotyping, FMR1 gene testing, subtelomeric fluorescence in situ hybridization (StFISH) testing, MeCP2 gene testing in girls with moderate to severe impairment, neuroimaging (MRI preferred to CT), and assessments for visual and hearing deficits. 3 Genetic advances prompted the development of this updated report focused solely on the diagnostic yield of genetic and metabolic testing.
DESCRIPTION OF THE ANALYTIC PROCESS
Literature searches for this evidence report were com-
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Supplemental data at www.neurology.org pleted for the years 1980 -2009 and resulted in 7,000 abstracts, 367 of which were selected for full-text review. See appendix e-2, a and b, on the Neurology ® Web site at www.neurology.org for information on databases searched, search terms used, and article classification. Table e-1 presents the diagnostic yield in different populations for various testing methods.
ANALYSIS OF EVIDENCE Genome-wide genetic
testing. Genetic evaluation of a child with GDD/ID who lacks distinctive syndromic features generally begins with genome-wide testing for DNA rearrangements. G-banded karyotyping detects chromosomal structural changes with a resolution of 3-5 million base pairs (3) (4) (5) . StFISH and microarray tests detect specific copy number changes (most commonly deletions or duplications) for which the specific probes are constructed. 4 Microarray tests based on bacterial artificial chromosome (BAC) probes typically have a resolution of 1 Mb, and those based on oligonucleotide probes typically have resolutions of 30,000 -35,000 base pairs (kb). Microarray testing detects well-known syndromes (e.g., Velo-cardio-facial syndrome or Williams syndrome) as well as previously undescribed genomic disorders. Interpretation of microarray abnormalities of uncertain significance will often require referral for a medical genetics consultation. Abnormal results are considered diagnostic when previously reported to be causative and are considered possibly diagnostic when absent in unaffected parents. 5 When abnormal results of uncertain significance are inherited from an unaffected parent, interpretation should be made cautiously, given the possibility of variable penetrance.
Microarray studies. The results of studies reporting microarray test yields are summarized in appendix e-3. Twenty-seven Class III studies of 6,559 subjects with GDD/ID found microarray testing to be diagnostic in 7.8% (range 0%-50%).
6 -32 A higher yield of 10.2% (0%-50%) was found in the 18 studies in which the 1,524 subjects were described as syndromic (facial dysmorphism, congenital anomalies, or neurologic symptoms). 6 -23 A lower yield of 6.4% was found in the one study in which all 94 subjects were described as nonsyndromic.
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G-banded karyotype studies. The results of studies reporting karyotype test yields are summarized in appendix e-4. A Class II study of 342 patients with unexplained GDD/ID found that 4% had an abnormal karyotype. 33 Nine Class III studies found a similar yield of 4.2% (2.9%-11.7%) in 4,032 patients. 34 -40,e1,e2 Three Class III studies of 70 subjects with syndromic GDD/ID found a much higher yield of 18.6% (6.7%-50%). 36,38,e3 StFISH studies. The results of studies reporting StFISH test yields are summarized in appendix e-5.
One Class I study found StFISH abnormalities in 5.9% of 466 patients with unexplained GDD/ID. Few studies have directly compared genome-wide genetic tests. One Class III study (n ϭ 94) comparing microarray with StFISH found abnormalities in 9 subjects, including 6 that were seen only by microarray. e44 The same study reported that 12% of 424 subjects with syndromic GDD/ID had microarray abnormalities, most of which were interstitial (i.e., not in areas screened by StFISH). Another Class III study of BAC-based microarray in 278 patients with GDD/ID found subtelomeric abnormalities in 3 patients who had prior normal StFISH test results. 30 Most studies of microarrays and StFISH tests were done on children whose karyotype testing had been normal. It is reasonable to hypothesize that the yields would have been higher if subjects were not initially screened by karyotyping.
Conclusions. Microarray testing is abnormal on average in 7.8% of subjects with GDD/ID and in 10.6% of those with syndromic features (Class III). Karyotype studies are abnormal in at least 4% of subjects with GDD/ID and in 18.6% of those with syndromic features (Class II and III). StFISH testing is abnormal in at least 3.5% of subjects with GDD/ID, in at least 4.2% of those with syndromic features, in as few as 0.5% of those with mild impairment, and in at least 7.4% of those with moderate/severe impairment (Class I, II, and III).
X-linked genetic testing. X-linked intellectual disability (XLID) is estimated to account for approximately 10% of all cases of ID. e45 More than 70 genes responsible for XLID in which mutations have been identified have been cloned. e46 There are more than 100
genes that have been identified by linkage and not yet cloned and another 9 segmental duplications of the X chromosome. X-linked ID gene studies. The results of studies reporting XLID gene test yields are summarized in appendix e-6. One Class III study compiled sequencing efforts from 600 families with multiple males affected by either GDD/ID or other neurologic abnormalities that remained unexplained after karyotype and FMR1 testing. e47 X-linkage was considered definite (DXL) in 325 families, possible (PXL) in 191 families, and unknown (UXL) in 84 families. Sixteen genes were sequenced in more than 100 families, and mutations were found in 42% of families with DXL and 17% of families with PXL. Mutations in XLID genes also were found in some males from UXL families.
The XLID genes tested individually in these families include the ARX, JAR1D1C, and SLC6A8 genes. One Class III study from the European XLMR cohort identified ARX mutations in 7.5% of 147 DXL families and 1.5% of 136 PXL families.
e48 Another Class III study found ARX mutations in 5% of 80 DXL families and 1.2% of 85 PXL families.
e49 Two Class III studies found JARID1C mutations in 3.1% of 323 DXL or PXL families.
e50,e51 One Class III study found JAR1D1C mutations in 8.6% of 23 DXL or PXL families, 0.6% of 172 UXL families, and 1.1% of 92 isolated males with short stature. One Class III study found SLC6A8 mutations in 2.1% of 288 patients from DXL or PXL families, e53 whereas another Class III study found SLC6A8 mutations in 0.4% of 478 unrelated males with unexplained GDD/ID. e54 FMR1 gene studies. The FMR1 gene at Xq27.3 normally contains 5-40 consecutive CGG trinucleotide repeats. When 55-200 repeats are present, the gene has an unstable "premutation" length that is prone to further expansion during meiosis. A full expansion to more than 200 repeats is associated with the dysmorphism, ID, and social impairment of fragile X syndrome.
The results of studies reporting FMR1 gene test yields are summarized in appendix e-7. Four Class II studies found full FMR1 expansions in 2% (0.7%-6.4%) of 2,226 patients (55.5% males) with unexplained mild/moderate GDD/ID. e55-e58 Another 17 Class III studies (n ϭ 24,216) found full expansions in 2.5% (0%-11.7%). 35,39,e59 -e73 Full FMR1 expansions were found in 2.6% (1%-8%) of 1,236 male subjects from 4 Class II studies e55-e58 and in 2.9% (2%-13.7%) of 15,698 male subjects from 6 Class III studies.
e61,e65,e67,e73-e75 Full FMR1 expansions were found in 1.3% (0%-7%) of 1,340 female subjects from 6 Class II studies e55-e58,e76,e77 and 1.1% (0.7%- Conclusions. Mutations in X-linked genes may explain up to 10% of all cases of GDD/ID. Testing of XLID genes has a yield of 42% in males from definitely X-linked families and of 17% in males from possibly X-linked families (Class III). FMR1 testing has a combined yield of at least 2% in male and female subjects with mild GDD/ID (Class II and III). MeCP2 mutations are found in 1.5% of girls with moderate/severe GDD/ID and in less than 0.5% of males with GDD/ID (Class III).
Metabolic testing. Inborn errors of metabolism (IEMs) are a diverse collection of disorders of intermediate (carbohydrate, amino acid, and lipid) metabolism that are caused by dysfunction of an enzyme encoded by a single gene. IEMs have wide phenotypic variation and can present with static encephalopathy but may be suspected on the basis of historical features (affected family members, parental consanguinity, episodic decompensation, developmental regression), physical findings (coarse facial features, organomegaly), or neuroimaging findings (abnormal myelination, striatal necrosis).
The results of studies reporting metabolic test yields are summarized in appendix e-9. One Class II study of 151 patients with GDD/ID found metabolic screening tests to have a 5% yield.
e96 Seven Class III studies found a yield of 1.8% (0%-4.6%) in 3,862 patients with GDD/ID. 40,e39,e97-e102 In one of these studies, selective IEM testing performed because of clinical suspicion was diagnostic in 8 -10 (range 3.7%-4.6%) of 216 patients with unexplained GDD/ID. e39 None of the 176 screening tests for plasma amino acids and urine organic acids was abnormal. Four children (1.4%) with congenital dis-orders of glycosylation (CDG) were identified by plasma sialotransferrin analysis, 2 children had abnormal serum cholesterol and 7-dehydrocholesterol levels suggestive of Smith-Lemli-Opitz syndrome, 2 had laboratory evidence of a mitochondrial disorder, 1 had laboratory evidence of a peroxisomal disorder, and 1 had abnormal CSF biogenic amine levels. In another of these Class III studies, metabolic testing was redone in 433 children whose GDD/ID remained unexplained after genetic/metabolic testing that included a standard karyotype; urine for amino acids, organic acids, mucopolysaccharides, oligosaccharides, uric acid, sialic acid, purines, and pyrimidines; and plasma for amino acids, acylcarnitines, and sialotransferrins.
e102 Screening tests were repeated, and additional testing, including CSF studies, was guided by clinical suspicion. IEMs were identified and confirmed in 12 patients (2.7%), including 3 with mitochondrial disorders, 2 with creatine transporter disorders, 2 with short-chain acylCoA dehydrogenase deficiency, and 1 each with Sanfilippo IIIa, a peroxisomal disorder, a CDG, 5-methyltetrahydrofolate reductase deficiency, and GLUT1 deficiency.
Several studies have screened for disorders of creatine synthesis and transport by measuring urine creatine and guanidinoacetate. One Class III study screened 188 male and female subjects with unexplained GDD/ID and identified 5 (2.7%) boys with severe to profound impairment who had abnormalities. e103 Another Class III study of 1,600 unrelated male and female children with GDD/ID and/or autism found that 34 (2.1%) had abnormal urine creatine-to-creatinine ratios, although only 10 (0.6%) had abnormal repeat tests and only 3 (0.2%) were found to have a mutation in the X-linked SLC6A8 gene. e104 As mentioned earlier, a Class III study found SLC6A8 mutations in 0.4% of 478 unrelated males with unexplained GDD/ ID. e105 Another Class III study of 180 institutionalized subjects with unexplained severe to profound GDD/ID found 5 (2.8%) with mutations in the autosomal GAMT gene, 2 (1.1%) of which were clearly pathologic. Conclusions. Screening for IEMs in children with GDD/ID has a yield of between 0.2% and 4.6%, depending on the presence of clinical indicators and the range of testing performed (Class III). Testing for CDGs has a yield of up to 1.4%, and testing for creatine synthesis and transport disorders has a yield of up to 2.8% (Class III).
CLINICAL CONTEXT We reviewed numerous studies that found yields of more than 1% for various genetic and metabolic tests in children with unexplained GDD/ID. Most of the studies were classified as providing Class III evidence because their subjects were drawn from referral-based neurology and genetics specialty clinics, where most decisions regarding testing are and will continue to be made. The yield of a given test is admittedly only one of many factors to be considered when planning a diagnostic testing strategy for a child with GDD or ID. Other factors include the ability of a test to identify a treatable disorder; the pretest probability of presence of a disease based on clinical features and family history; and the availability, invasiveness, and cost of testing.
An etiologic diagnosis for GDD or ID only occasionally leads to a specific therapy that improves the child's outcome; however, it often leads to other benefits for the child and the child's family. These benefits include relieving caregivers of anxiety and uncertainty, empowering caregivers to become involved in support and research networks, limiting further diagnostic testing that may be costly or invasive, improving understanding of treatment and prognosis, anticipating and managing associated medical and behavioral comorbidities, allowing for counseling regarding recurrence risk, and preventing recurrence through screening for carriers and prenatal testing. The evaluation of children with neurodevelopmental disabilities is evolving as previously unrecognized disease mechanisms are uncovered and novel and increasingly sensitive methods for diagnosis are introduced, improving etiologic yields.
e108 Physicians who develop their familiarity with the clinical features and testing of genetic and metabolic disorders will likely be more efficient in their patient evaluations, ordering fewer tests rather than more. Many children seen for GDD/ID do not present with syndromic features or a positive family history.
Microarray is the genetic test with the highest diagnostic yield in children with unexplained GDD/ID. The resolution of the current generation of commercially available, genome-wide, oligonucleotide-based microarray testing is 700 base pairs, 30 to 40 times higher than the oligo-based tests previously used in studies of GDD/ID and 1,000 times higher than older BAC-based microarrays. Laboratories now offer single nucleotide polymorphism sensitive microarray that detects and describes consanguinity or uniparental disomy. Studies on the yield of these more advanced microarray tests are anticipated in the near future. Currently, microarray testing can identify only unbalanced copy number changes and is insufficiently sensitive for detecting genetic disorders caused by inversions, balanced insertions, reciprocal translocations, polyploidy, low-level mosaicism (Ͻ20%-25%), rearrangements in repeat sequences, point mutations, or duplications/deletions that are undetectable at the test's resolution level. The results of microarray testing are often complex and require confirmation and careful interpretation, often with the assistance of a medical geneticist.
The other genome-wide genetic tests reviewed, G-banded karyotyping and StFISH testing, have a lower sensitivity for abnormalities in similar populations of children with unexplained GDD/ID. There is consensus among clinical geneticists that microarrays should be considered first-line cytogenetic tests, preferred over StFISH testing and karyotyping, with karyotyping reserved for patients having signs of a specific chromosomal syndrome (e.g., Down syndrome), a family history of a chromosomal rearrangement, or a parent with a history of multiple miscarriages.
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Males with a history strongly suggestive of X-linked inheritance may be considered for testing of one or more individual XLID genes or for screening of the entire X chromosome. Girls with severe impairment may be appropriate for testing for MeCP2 mutations, regardless of whether the specific clinical features of Rett syndrome are present.
There may be greater suspicion for IEMs in children whose parents either are consanguineous or have had children with similar problems or unexplained death or fetal demise. Children with IEMs may have multiple organ system dysfunction, failure to thrive, dietary selectivity, unusual odors, hearing loss, or episodic symptoms, including seizures or encephalopathy. The importance of considering IEMs requires emphasis, because for some entities specific dietary or metabolic treatments may improve neurologic symptoms.
In addition to the clinical matters considered above it is important to remember that genetic testing is costly and may not be available to all families. Some of the critical matters related to the cost analysis of performing microarray testing are summarized in appendix e-11.
RECOMMENDATIONS FOR FUTURE RESEARCH
1. Further prospective studies on the etiologic yields of various diagnostic tests need to be undertaken on large numbers of young children with GDD/ID and control subjects. Such studies should include newer molecular genetic and MRI technologies. With the resulting data, prospective testing of specific evaluation paradigms will be possible. 2. Features (i.e., markers) present on the history and physical examination at intake need to be identified that will improve specific evaluation strategies and enhance etiologic yield. 
DISCLAIMER
This statement is provided as an educational service of the American Academy of Neurology and the Child Neurology Society. It is based on as assessment of current scientific and clinical information. It is not intended to include all possible proper methods of care for a particular neurological problem or all legitimate criteria for choosing to use a specific procedure.
Neither is it intended to exclude any reasonable alternative methodologies. The AAN and the CNS recognize that specific patient care decisions are the prerogative of the patient and the physician caring for the patient, based on all of the circumstances involved. The clinical context section is made available in order to place the evidence into perspective with current practice habits and challenges. No formal practice recommendations should be inferred.
